keyword
MENU ▼
Read by QxMD icon Read
search

Gynecologic carcinoma

keyword
https://www.readbyqxmd.com/read/28807367/an-evaluation-of-progression-free-survival-and-overall-survival-of-ovarian-cancer-patients-with-clear-cell-carcinoma-versus-serous-carcinoma-treated-with-platinum-therapy-an-nrg-oncology-gynecologic-oncology-group-experience
#1
Kate E Oliver, William E Brady, Michael Birrer, David M Gershenson, Gini Fleming, Larry J Copeland, Krishnansu Tewari, Peter A Argenta, Robert S Mannel, Angeles Alvarez Secord, Jean-Marie Stephan, David G Mutch, Frederick B Stehman, Franco M Muggia, Peter G Rose, Deborah K Armstrong, Michael A Bookman, Robert A Burger, John H Farley
PURPOSE: We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). METHODS: We reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). RESULTS: There were 10,803 patients enrolled, 9531 were eligible, evaluable and treated with platinum, of whom 544 (6%) had OCCC, 7054 (74%) had SOC, and 1933 (20%) had other histologies and are not included further...
August 11, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28807231/bartholin-gland-cancer
#2
REVIEW
Violante Di Donato, Assunta Casorelli, Erlisa Bardhi, Flaminia Vena, Marchetti Claudia, Ludovico Muzii, Pierluigi Benedetti Panici
INTRODUCTION: Bartholin gland carcinoma is an extremely rare condition. Because of its, phase III trials have not been carried out, there exists no unanimous consensus on treatment and guidelines are missing. METHODS: All studies reporting cases of Bartholin cancer were collected and screened for the evaluations. Baseline characteristics of studies were extracted and were queried in a database. RESULTS: A total number of 133 manuscripts collected were available for the review process, representing a total number of 275 reported cases...
September 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28804555/imp3-is-upregulated-in-primary-ovarian-mucinous-carcinoma-and-promotes-tumor-progression
#3
Qin Zhu, Yuqing Qu, Qiongyan Zhang, Linghui Lu, Weiwei Weng, Hao Zhang, Lihong Zhang, Yan Ning, Yiqin Wang
OBJECTIVE: Primary ovarian mucinous tumors progress from benign adenoma to borderline tumors to invasive mucinous carcinoma. A proper differential diagnosis is crucial to discriminate malignancies at the early stages of disease. However, few biomarkers are clinically available. We designed this study to analyze the clinical application of the oncogene IMP3 in monitoring early malignancies in ovarian primary mucinous tumors. METHODS: We collected 250 samples of ovarian primary mucinous tumors along with the corresponding clinicopathological information between 2009 and 2015 at the Gynecology and Obstetrics Hospital of Fudan University and performed immunochemical assays...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28800941/survival-and-safety-associated-with-aggressive-surgery-for-stage-iii-iv-epithelial-ovarian-cancer-a-single-institution-observation-study
#4
Shinichi Tate, Kazuyoshi Kato, Kyoko Nishikimi, Ayumu Matsuoka, Makio Shozu
OBJECTIVE: We evaluated the efficacy and safety of aggressive surgery for advanced ovarian cancer at a non-high-volume center. MATERIALS AND METHODS: We evaluated consecutive patients with stage III/IV ovarian, fallopian, and peritoneal cancer undergoing elective aggressive surgery from January 2008 to December 2012, which encompassed the first 5years after implementing an aggressive surgery protocol. After receiving appropriate training for 9months, a gynecological surgical team began performing multi-visceral resections...
August 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28797999/long-term-results-of-post-operative-pelvic-image-guided-intensity-modulated-radiotherapy-in-gynecological-malignancies
#5
Rashi Agrawal, Sowmiya Prithiviraj, Dinesh Singh, Vaishali Zamre, Sandeep Agrawal, Arun Kumar Goel, Kanika Gupta, Bala Subramanian
OBJECTIVE: To assess late clinical outcomes with image guided intensity modulated radiotherapy (IG- IMRT) in gynecological malignancies. PATIENTS AND METHODS: We have been practicing IG IMRT for gynecological malignancies since January 2009. Here we are presenting our experience with this modern technique at median follow up of 38 months. During whole treatment bladder filling protocol was followed. Both target volumes and critical structures were contoured according to RTOG guidelines...
May 2017: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28796747/morphologic-and-immunohistochemical-study-of-clear-cell-carcinoma-of-the-uterine-endometrium-and-cervix-in-comparison-to-ovarian-clear-cell-carcinoma
#6
Baohui Ju, Jianmei Wang, Bo Yang, Lin Sun, Yuhong Guo, Quan Hao, Jianghua Wu
Endometrial clear cell carcinoma (ECCC) and clear cell adenocarcinoma of the cervix (CCAC) are uncommon gynecologic cancers that have morphologic and phenotypic features similar to ovarian clear cell carcinoma (OCCC), but the 3 entities may not be completely identical. This study identified the morphologic and phenotypic characteristics and the differences between ECCC and CCAC in Comparison to OCCC. The morphologic features of 16 ECCCs, 7 CCACs, and 22 OCCCs are described. The immunoprofiles of hepatocyte nuclear factor (HNF) 1β, napsin A, estrogen, progesterone, p53, and Ki-67 were assessed...
August 7, 2017: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/28796031/anti-yo-positive-and-late-onset-paraneoplastic-cerebellar-degeneration-associated-with-ovarian-carcinoma-a-case-report
#7
Dan Cui, Li Xu, Wen-Yi Li, Wei-Dong Qian
RATIONALE: Paraneoplastic cerebellar degeneration (PCD) is a rare nonmetastatic neurological complication often associated with ovarian, breast, and other gynecologic cancers. Anti-Yo is one of the antionconeural antibodies found in patients with PCD. It primarily emerges before a malignancy is detected. PATIENT CONCERNS: In this report, we describe an unusual case involving a patient who exhibited anti-Yo-positive PCD 1 year after being diagnosed with ovarian cancer...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28795841/serous-carcinoma-mimicking-primary-urothelial-carcinoma-on-clinical-evaluation-and-pathology-a-potential-diagnostic-pitfall
#8
Leili Mirsadraei, Alexey Hodkoff, Karra Jones, Ahmed Shabaik, A Karim Kader, Cheryl C Saenz, Rodolfo Montironi, David E Tacha, Oluwole Fadare, Donna E Hansel
CONTEXT: - Serous carcinoma of the gynecologic tract often involves the external bladder wall and can occasionally mimic primary urothelial carcinoma of the bladder. OBJECTIVE: - To define the spectrum of morphologic and immunohistochemical features that characterize serous carcinoma involving the bladder wall and its distinction from urothelial carcinoma. DESIGN: - We reviewed all cases of serous carcinoma secondarily involving the bladder wall from the University of California San Diego and Polytechnic Institute for histopathologic and immunohistochemical features...
August 10, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28791387/atelocollagen-mediated-in-vivo-sirna-transfection-in-ovarian-carcinoma-is-influenced-by-tumor-site-sirna-target-and-administration-route
#9
Matthieu Meryet-Figuière, Charlotte Lecerf, Emilie Varin, Jean-Luc Coll, Marie-Hélène Louis, Soizic Dutoit, Florence Giffard, Cécile Blanc-Fournier, Siham Hedir, Nicolas Vigneron, Emilie Brotin, Laurent Pelletier, Véronique Josserand, Christophe Denoyelle, Laurent Poulain
Ovarian cancer is the leading cause of death from gynecological malignancies worldwide, and innate or acquired chemoresistance of ovarian cancer cells is the major cause of therapeutic failure. It has been demonstrated that the concomitant inhibition of Bcl-xL and Mcl-1 anti-apoptotic activities is able to trigger apoptosis in chemoresistant ovarian cancer cells. In this context, siRNA-mediated Bcl‑xL and Mcl-1 inhibition constitutes an appealing strategy by which to eliminate chemoresistant cancer cells...
August 4, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28791369/cepharanthine-hydrochloride-reverses-p%C3%A2-glycoprotein-mediated-multidrug-resistance-in-human-ovarian-carcinoma-a2780-taxol-cells-by-inhibiting-the-pi3k-akt-signaling-pathway
#10
Chen-Zheng Huang, Ya-Feng Wang, Yan Zhang, You-Mei Peng, Yi-Xian Liu, Fang Ma, Jin-Hua Jiang, Qing-Duan Wang
Ovarian cancer has the highest mortality rate among gynecologic malignant tumors. The major obstacle to treatment success is multidrug resistance (MDR) to chemotherapy drugs. Cepharanthine hydrochloride (CH), a natural alkaloid-derived compound, has shown MDR reversal potency in several tumor cell lines; however, the molecular mechanism is not entirely known. In the present study, we assessed whether CH sensitized malignant cells to chemotherapy drugs in ovarian cancer and explored the relevant mechanism. We found that CH reduced the IC50 value of paclitaxel and increased intracellular rhodamine-123 accumulation in human ovarian cancer A2780/Taxol cells in a concentration-dependent manner...
August 4, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28791269/primary-mucinous-adenocarcinoma-of-the-vulva-intestinal-type
#11
In Ho Lee, Mi Kyung Kim, Yoo Kyung Lee, Sung Ran Hong, Ki Heon Lee
Primary vulva malignancy is a rare gynecologic malignancy. Most of them are squamous cell carcinomas and adenocarcinomas are much less common. Intestinal type is a rare variant of primary adenocarcinoma of the vulva. It histologically resembles mucinous colonic carcinomas. Origin from cloacal remnants has been suggested but remains speculative. A 64-year-old woman was referred to our clinic with a 1-month history of an itching vulva mass. An incisional biopsy was performed at other hospital and disclosed adenocarcinoma of intestinal type...
July 2017: Obstetrics & Gynecology Science
https://www.readbyqxmd.com/read/28782867/imaging-in-gynecological-disease-11-clinical-and-ultrasound-features-of-mucinous-ovarian-tumors
#12
F Moro, G F Zannoni, D Arciuolo, T Pasciuto, S Amoroso, F Mascilini, S Mainenti, G Scambia, A C Testa
OBJECTIVE: To describe the clinical and ultrasound findings in patients with mucinous ovarian tumors. METHODS: In this retrospective study, women with a histological diagnosis of mucinous ovarian tumor who had undergone preoperative ultrasound examination were identified from the database of a single ultrasound center. The histological examination was performed by the same pathologist in all cases, and the ultrasound appearance of the tumors was described using the terms and definitions of the International Ovarian Tumor Analysis group...
August 2017: Ultrasound in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/28782618/updates-on-conservative-management-of-endometrial-cancer
#13
REVIEW
Camila Corzo, Natalia Barrientos Santillan, Shannon N Westin, Pedro T Ramirez
Endometrial cancer is the most common gynecologic cancer in the United States. It is typically diagnosed in postmenopausal women. However, given the increasing incidence of risk factors such as obesity and diabetes in younger women, it is becoming a more prevalent problem in this age group. When endometrial cancer is diagnosed in patients of reproductive age, the standard surgical option of hysterectomy and bilateral salpingo-oophorectomy may not be ideal for women interested in future fertility. Hence, conservative options for select patients should be discussed along with the associated outcomes of each approach...
August 3, 2017: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/28777143/assessing-tumor-infiltrating-lymphocytes-in-solid-tumors-a-practical-review-for-pathologists-and-proposal-for-a-standardized-method-from-the-international-immuno-oncology-biomarkers-working-group-part-2-tils-in-melanoma-gastrointestinal-tract-carcinomas-non
#14
Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen van de Vijver, M V Estrada, Paula I Gonzalez-Ericsson, Melinda Sanders, Benjamin Solomon, Cinzia Solinas, Gert G G M Van den Eynden, Yves Allory, Matthias Preusser, Johannes Hainfellner, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria, Fraser Symmans, Paolo Nuciforo, Laura Comerma, E A Thompson, Sunil Lakhani, Seong-Rim Kim, Stuart Schnitt, Cecile Colpaert, Christos Sotiriou, Stefan J Scherer, Michail Ignatiadis, Sunil Badve, Robert H Pierce, Giuseppe Viale, Nicolas Sirtaine, Frederique Penault-Llorca, Tomohagu Sugie, Susan Fineberg, Soonmyung Paik, Ashok Srinivasan, Andrea Richardson, Yihong Wang, Ewa Chmielik, Jane Brock, Douglas B Johnson, Justin Balko, Stephan Wienert, Veerle Bossuyt, Stefan Michiels, Nils Ternes, Nicole Burchardi, Stephen J Luen, Peter Savas, Frederick Klauschen, Peter H Watson, Brad H Nelson, Carmen Criscitiello, Sandra O'Toole, Denis Larsimont, Roland de Wind, Giuseppe Curigliano, Fabrice André, Magali Lacroix-Triki, Mark van de Vijver, Federico Rojo, Giuseppe Floris, Shahinaz Bedri, Joseph Sparano, David Rimm, Torsten Nielsen, Zuzana Kos, Stephen Hewitt, Baljit Singh, Gelareh Farshid, Sibylle Loibl, Kimberly H Allison, Nadine Tung, Sylvia Adams, Karen Willard-Gallo, Hugo M Horlings, Leena Gandhi, Andre Moreira, Fred Hirsch, Maria V Dieci, Maria Urbanowicz, Iva Brcic, Konstanty Korski, Fabien Gaire, Hartmut Koeppen, Amy Lo, Jennifer Giltnane, Marlon C Rebelatto, Keith E Steele, Jiping Zha, Kenneth Emancipator, Jonathan W Juco, Carsten Denkert, Jorge Reis-Filho, Sherene Loi, Stephen B Fox
Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma...
August 2, 2017: Advances in Anatomic Pathology
https://www.readbyqxmd.com/read/28768676/role-of-metastasectomy-and-chemotherapy-in-carcinoma-of-uterine-cervix
#15
Nasir Ali, Muhammad Atif Mansha, Ahmed Nadeem Abbasi, Bilal Mazhar Qureshi
Squamous cell carcinoma of uterine cervix is potentially a curable disease; however, many patients treated with definitive chemoradiotherapy develop distant metastases, with few of them having a single metastatic deposit. There are no guidelines for the treatment of patients with oligometastatic cervical cancer.We present a case of a patient with International Federation of Gynecology and Obstetrics (FIGO) Stage IIB squamous cell carcinoma of uterine cervix. She was successfully treated with concurrent chemoradiotherapy with definitive intent...
August 2, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28768570/primary-cytoreductive-surgery-and-adjuvant-hormonal-monotherapy-in-women-with-advanced-low-grade-serous-ovarian-carcinoma-reducing-overtreatment-without-compromising-survival
#16
Amanda N Fader, Jennifer Bergstrom, Amelia Jernigan, Edward J Tanner, Kara Long Roche, Rebecca L Stone, Kimberly L Levinson, Stephanie Ricci, Stephanie Wethingon, Tian-Li Wang, Ie-Ming Shih, Bin Yang, Gloria Zhang, Deborah K Armstrong, Stephanie Gaillard, Chad Michener, Robert DeBernardo, Peter G Rose
OBJECTIVES: Women with advanced-stage, low-grade serous ovarian carcinoma (LGSC) have low chemotherapy response rates and poor overall survival. Most LGSC tumors overexpress hormone receptors, which represent a potential treatment target. Our study objective was to determine the outcomes of patients with advanced-stage LGSC treated with primary cytoreductive surgery (CRS) and hormone therapy (HT). METHODS: A retrospective study was performed at two academic cancer centers...
July 30, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28763369/sentinel-lymph-node-biopsy-in-the-management-of-vulvar-carcinoma-an-evidence-based-insight
#17
Mark R Brincat, Yves Muscat Baron
OBJECTIVE: Lymph node metastasis has been shown to represent the most significant prognostic factor in vulvar carcinoma. Because only 25% to 35% of patients with early stage disease have lymph node metastases, a significant 65% to 75% possibly do not benefit from elective inguinofemoral lymphadenectomy considering the related morbidities of wound infection, breakdown, and lower limb lymphedema. This review article aims to present and summarize the evidence available with regard to sentinel lymph node (SLN)-guided management of vulvar carcinoma...
August 1, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28763364/adjuvant-therapy-use-and-survival-in-stage-ii-endometrial-cancer
#18
Nataniel H Lester-Coll, Melissa R Young, Henry S Park, Elena S Ratner, Babak Litkouhi, Shari Damast
OBJECTIVE: Radiotherapy (RT) is an established adjuvant treatment for stage II endometrioid endometrial carcinoma (EEC). The role of chemotherapy (CT) in stage II EEC is less proven. We used the National Cancer Data Base to identify factors associated with adjuvant CT in stage II EEC and to explore whether receipt of CT was associated with improved overall survival (OS). METHODS/MATERIALS: Women diagnosed in 2010 to 2013 with International Federation of Obstetrics and Gynecology stage II EEC (grades 1-3) after hysterectomy and bilateral salpingo-oophorectomy were identified in the National Cancer Data Base...
August 1, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28761025/eleven-year-review-of-data-on-pap-smears-in-saudi-arabia-we-need-more-focus-on-glandular-abnormalities
#19
Haitham Nasser, Mohammad AlAyyaf, Azza Atallah, Mohammad Aminulislam, Lubna Rizwan, Abdulsalam Aodah, Yasser Alkahtani, Haifa Alshammari, Ahmed Alsayed, Susan Szpunar
BACKGROUND: We reviewed data from Saudi Arabia on epithelial cell abnormalities (ECA) detected by Pap smear after noticing a slight increase in the incidence of cervical glandular abnormalities in our regional laboratory in recent years. OBJECTIVE: Clarify data on adenocarcinoma (ADCA) on Pap smears in Saudi Arabia. DESIGN: Descriptive, retrospective study. SETTINGS: Regional laboratory, Riyadh. PATIENTS AND METHODS: We reviewed all Pap smears of adult females between 2006 and 2016 and compared our data with previously published results from Saudi Arabia...
July 2017: Annals of Saudi Medicine
https://www.readbyqxmd.com/read/28757766/clear-cell-carcinoma-arising-from-scar-endometriosis-a-case-report-and-literature-review
#20
Chun-Jui Wei, Shu-Han Huang
Scar endometriosis is uncommon and defined as the presence of ectopic endometrial glands in abdominal soft tissues after a gynecological operation. Malignant transformation has been reported but remains rare. Carcinogenesis occurs in ectopic endometrial tissue with repeated hormone stimulation during the menstrual cycle. We present a case of clear cell carcinoma directly arising from scar endometriosis after a cesarean section and review all 16 cases reported.
January 2017: Ci Ji Yi Xue za Zhi, Tzu-chi Medical Journal
keyword
keyword
36691
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"